Jubilant Pharmova Current Share Price | Jubilant Pharmova Stock Screener
JUBLPHARMA
Pharmaceuticals
Jubilant Pharmova Current Stock Price Today
Live Share Price NSE
₹1065.40
▲
53.30 (5.27%)
Live Share Price BSE
₹1067.15
▲
55.10 (5.44%)
As of September 18, 2026, the live Jubilant Pharmova share price (NSE: JUBLPHARMA) is ₹1,065.40 on NSE and ₹1,067.15 on BSE, up 5.27% from the previous close, with shares trading between ₹1,012.10 and ₹1,086.00 in today's trading session, and a 52-week range of ₹807.65–₹1,181.20.
Browse JUBLPHARMA annual financials to support your investment research.
Use the Jubilant Pharmova stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Jubilant Pharmova Market Cap
₹16,329.50 Cr.
JUBLPHARMA P/E Ratio (TTM)
46.50
Jubilant Pharmova P/B Ratio
2.30
EPS (TTM)
₹25.15
Dividend Yield
0.49%
Debt to Equity
0.48
JUBLPHARMA 52 Week High
₹1181.20
Jubilant Pharmova 52 Week Low
₹807.65
Operating Margin
14.00%
Profit Margin
5.18%
JUBLPHARMA Revenue (TTM)
₹2,296.00
EBITDA
₹332.00
Net Income
₹119.00
Total Assets
₹15,523.00
Total Equity
₹7,096.00
Jubilant Pharmova Current Share Price Chart
Track the current Jubilant Pharmova share price and stock price with an interactive chart. Analyse JUBLPHARMA price trends, trading volume, historical performance, and volatility across different timeframes — the complete Jubilant Pharmova stock quote in one place.
Jubilant Pharmova Company Profile - Fundamental Screener
Screen Jubilant Pharmova company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for JUBLPHARMA shares.
Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company. It operates in segments including Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, and Proprietary Novel Drugs. The company manufactures and supplies Active Pharmaceutical Ingredients, Solid Dosage Formulations, Radiopharmaceuticals, and...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Shyam S Bhartia
ISIN
INE700A01033
Website
https://www.jubl.com
Jubilant Pharmova Balance Sheet Screener
Screen JUBLPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 15,523 | 12,756 | 11,549 | 11,157 | 9,991 | 8,918 | 12,522 | 11,469 | 9,618 | 9,041 |
| Current Assets | 4,109 | 3,577 | 3,876 | 3,762 | 3,509 | 2,953 | 5,038 | 4,585 | 3,190 | 2,948 |
| Fixed Assets | 6,966 | 5,176 | 5,091 | 5,183 | 4,871 | 4,609 | 6,340 | 5,648 | 5,401 | 5,107 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 5,888 | 4,353 | 4,238 | 3,993 | 3,083 | 3,128 | 4,299 | 4,570 | 3,578 | 3,968 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 7,096 | 6,239 | 5,421 | 5,392 | 5,316 | 4,742 | 5,604 | 4,809 | 4,035 | 3,389 |
| Share Capital | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves & Surplus | 7,077 | 6,239 | 5,418 | 5,383 | 5,303 | 4,726 | 5,588 | 4,793 | 4,071 | 3,421 |
Jubilant Pharmova Income Statement Screener - Profit & Revenue Analysis
Screen Jubilant Pharmova income statement and profit fundamentals.
Analyze JUBLPHARMA quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Jubilant Pharmova share price evaluation.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,296 | 2,241 | 1,928 | 1,891 | 1,968 | 2,137 | 1,764 | 2,130 | 1,764 | 1,823 | 1,682 | 1,575 | 1,686 | 1,714 | 1,513 |
| Expenses | 1,964 | 1,981 | 1,587 | 1,611 | 1,631 | 1,873 | 1,656 | 1,480 | 1,477 | 1,554 | 1,459 | 1,419 | 1,439 | 1,459 | 1,280 |
| EBITDA | 332 | 260 | 341 | 280 | 337 | 264 | 108 | 650 | 287 | 269 | 223 | 156 | 247 | 255 | 233 |
| Operating Profit % | 14.00% | 11.00% | 17.00% | 14.00% | 17.00% | 12.00% | 5.00% | 14.00% | 15.00% | 14.00% | 12.00% | 9.00% | 14.00% | 12.00% | 15.00% |
| Depreciation | 117 | 127 | 95 | 98 | 105 | 121 | 101 | 91 | 91 | 91 | 271 | 90 | 97 | 95 | 101 |
| Interest | 57 | 54 | 53 | 49 | 50 | 56 | 73 | 71 | 61 | 56 | 56 | 62 | 66 | 71 | 40 |
| Profit Before Tax | 176 | 86 | 206 | 154 | 190 | 93 | -54 | 500 | 144 | 131 | -86 | 25 | 98 | 101 | 106 |
| Tax | 57 | 30 | 55 | 52 | 70 | 38 | 8 | 18 | 42 | 30 | 14 | 19 | 36 | 35 | 47 |
| Net Profit | 119 | 56 | 151 | 103 | 120 | 56 | -62 | 482 | 103 | 101 | -101 | 6 | 62 | 66 | 59 |
| EPS | 7.55 | 3.57 | 9.71 | 6.49 | 7.59 | 3.52 | -3.69 | 30.44 | 6.47 | 6.37 | -6.15 | 0.40 | 3.94 | 4.22 | 3.74 |
Jubilant Pharmova Cash Flow Screener - Liquidity Fundamentals
Screen JUBLPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,227 | 1,072 | 971 | 661 | 838 | 1,784 | 1,543 | 1,122 | 1,303 | 1,269 |
| Investing Activities | -1,143 | 513 | -596 | -474 | -323 | -727 | -267 | -1,018 | -614 | -465 |
| Financing Activities | 95 | -1,453 | -433 | -157 | -33 | -1,709 | -1,050 | 657 | -901 | -686 |
| Net Cash Flow | 179 | 132 | -58 | 30 | 482 | -652 | 225 | 761 | -212 | 117 |
Jubilant Pharmova Shareholding Pattern Screener
See Jubilant Pharmova shareholding pattern with promoter, FII, and DII holdings.
Check Jubilant Pharmova promoter holding and ownership changes for JUBLPHARMA on TickJournal.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 47.68% | 47.68% | 50.68% | 47.68% | 47.68% | 47.68% | 50.68% | 50.68% |
| FII Holding | 15.90% | 15.87% | 17.22% | 17.40% | 16.57% | 15.96% | 19.06% | 19.49% |
| DII Holding | 11.62% | 12.40% | 7.05% | 9.53% | 10.52% | 11.22% | 3.78% | 4.07% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 17.57% | 17.16% | 17.75% | 17.97% | 18.02% | 17.85% | 18.71% | 17.79% |
| Other Holding | 7.23% | 6.89% | 7.31% | 7.42% | 7.22% | 7.29% | 7.77% | 7.97% |
| Shareholder Count | 86,347 | 82,703 | 96,526 | 99,673 | 93,336 | 90,133 | 92,264 | 81,992 |
Jubilant Pharmova Share Dividend Screener - Share Yield Analysis
Check Jubilant Pharmova dividend history with payout and yield data.
View Jubilant Pharmova dividend details including ex-dates and amounts for JUBLPHARMA stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹5.00 | 0.49% |
| 2025-March | ₹5.00 | 0.61% |
| 2024-March | ₹5.00 | 0.56% |
| 2023-March | ₹5.00 | 0.88% |
| 2022-March | ₹5.00 | 1.79% |
| 2021-March | ₹5.00 | 1.29% |
| 2020-March | ₹5.00 | 0.73% |
| 2019-March | ₹4.50 | 1.81% |
| 2018-March | ₹3.00 | 0.45% |
| 2017-March | ₹3.00 | 0.36% |
Jubilant Pharmova Stock Index Membership
See which indices include Jubilant Pharmova stock.
Check JUBLPHARMA index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
NIFTY 500
NIFTY MIDSML 400
NIFTY SMLCAP 250
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MOMENTUM 50
NIFTY500 MULTICAP
Jubilant Pharmova Market Events Screener - Corporate Actions
Get Jubilant Pharmova corporate actions including splits, bonuses, and buybacks.
Check Jubilant Pharmova stock events that may affect JUBLPHARMA share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-26 | 2026-08-26 | Annual General Meeting | NA | -6.93% |
| 2026-08-10 | 2026-08-10 | Quarterly Result Announcement | NA | -4.69% |
| 2026-07-24 | 2026-07-24 | Dividend | ₹ 5.00 /share | -4.03% |
| 2026-05-22 | 2026-05-22 | Quarterly Result Announcement | NA | 6.91% |
| 2026-02-06 | 2026-02-06 | Quarterly Result Announcement | NA | 2.93% |
| 2025-10-31 | 2025-10-31 | Quarterly Result Announcement | NA | 1.90% |
| 2025-08-29 | 2025-08-29 | Annual General Meeting | NA | -7.13% |
| 2025-07-29 | 2025-07-29 | Quarterly Result Announcement | NA | -2.98% |
| 2025-07-25 | 2025-07-25 | Dividend | ₹ 5.00 /share | 29.75% |
| 2025-05-16 | 2025-05-16 | Quarterly Result Announcement | NA | 1.03% |
| 2025-01-31 | 2025-01-31 | Quarterly Result Announcement | NA | 1.84% |
| 2024-10-25 | 2024-10-25 | Quarterly Result Announcement | NA | -9.79% |
| 2024-08-30 | 2024-08-30 | Annual General Meeting | NA | 8.43% |
| 2024-08-02 | 2024-08-02 | Dividend | ₹ 5.00 /share | 23.06% |
| 2023-08-10 | 2023-08-10 | Dividend | ₹ 5.00 /share | 11.53% |
Jubilant Pharmova Competitors Screener - Peer Comparison
Screen JUBLPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 441,478 | 36.91 | 61,674 | 12.69% | 11,565 | 34.00 |
| Divis Laboratories | 247,470 | 85.36 | 11,067 | 13.95% | 2,568 | 63.65 |
| Torrent Pharmaceuticals | 188,872 | 86.95 | 13,886 | 20.34% | 2,138 | 52.16 |
| Zydus Life Science | 112,608 | 24.28 | 27,658 | 17.64% | 5,026 | 45.64 |
| Cipla | 110,352 | 33.22 | 29,045 | 2.24% | 3,870 | 35.27 |
| Laurus Labs | 106,298 | 95.94 | 6,868 | 22.01% | 890 | 68.28 |
| Dr Reddys Laboratories | 97,281 | 29.91 | 35,059 | 3.90% | 4,158 | 47.72 |
| Aurobindo Pharma | 96,652 | 25.88 | 34,145 | 5.56% | 3,503 | 57.04 |
| Lupin | 95,790 | 17.09 | 29,039 | 26.75% | 5,356 | 28.17 |
| Mankind Pharma | 94,163 | 44.87 | 14,636 | 14.85% | 1,938 | 37.57 |
Jubilant Pharmova Company Announcements - News Screener
Screen JUBLPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-09-17 | Update On USFDA Spokane | - |
| 2026-09-01 | Receipt Of Show Cause Notice By Jubilant Pharmova Limited - GST | - |
| 2026-08-29 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-28 | Receipt Of Show Cause Notice - Jubilant Generics Limited | - |
| 2026-08-26 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-08-26 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-08-23 | USFDA Approval For Line 3 Contract Manufacturing Facility Spokane U.S.A | - |
| 2026-08-17 | Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | - |
| 2026-08-17 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2026-08-11 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-10 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-08-10 | Un-Audited Standalone & Consolidated Financial Results For The Quarter Ended June 30 2026 | - |
| 2026-08-10 | Board Meeting Outcome for Meeting Held On August 10 2026 | - |
| 2026-08-05 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-08-05 | Board Meeting Intimation for Postponement And Rescheduling Of Board Meeting Scheduled For August 10 2026 | - |
| 2026-08-02 | Newspaper Advertisements Titled Notice Of 48Th Annual General Meeting E-Voting Record Date And Final Dividend Information | - |
| 2026-08-01 | Intimation To Shareholders About Deduction Of Tax At Source (TDS) On Final Dividend For FY 2025-26 If Approved By The Members At The Ensuing AGM | - |
| 2026-08-01 | Intimation Regarding Letter Dispatched To The Shareholders Whose Email Ids Are Not Registered For AGM Notice TDS Communication And Annual Report Of The Company For FY 2025-26 | - |
| 2026-08-01 | Business Responsibility and Sustainability Reporting (BRSR) | - |
| 2026-08-01 | Please Find Attached Herewith The Notice Of 48Th Annual General Meeting Alongwith The Annual Report For The Financial Year 2025-26. The 48Th AGM Of The Company Will Be Held On Wednesday August 26 2026 Through Video Conferencing / Other Audio Visual Means. | - |